Top

International Urology and Nephrology

Published in:

01-10-2016 | Urology - Original Paper

It is unnecessary to completely mobilize the kidney in retroperitoneoscopic renal pedicle lymphatic disconnection for intractable chyluria

Authors: Tao Zhang, Jinyou Wang, Dexin Yu, Jiaxing Ma, Haoqiang Shi, Liangkuan Bi, Dongdong Xie, Yi Wang, Jie Min

Published in: International Urology and Nephrology | Issue 10/2016

Abstract

Purpose

To compare the efficacy and safety of two approaches in retroperitoneoscopic renal pedicle lymphatic disconnection (RRPLD) for intractable chyluria: completely or partly mobilize the kidney.

Materials and methods

Retrospectively reviewed the clinical data of 77 patients, who underwent RRPLD because of intractable chyluria in our institution. We mobilized the whole affected kidney in 22 patients during the operation, but only dissected the lower part in other 55 patients. Operative time, blood loss, visual analog scale (VAS) score, postoperative bed rest, postoperative hospital stay, recurrence, intraoperative and postoperative complications were compared between the two groups.

Results

All operation was successful, and none convert to open. The chyluria was resolved immediately after surgery. Compared with completely mobilized RRPLD (CMR), partly mobilized RRPLD (PMR) was superior in terms of operative time (132.91 ± 35.65 vs. 91.73 ± 24.14 min), blood loss (35.68 ± 8.21 vs. 25.09 ± 7.41 ml), VAS score (4.63 ± 0.44 vs. 2.34 ± 0.80), postoperative bed rest (3.36 ± 0.49 vs. 1.80 ± 0.85 days) and hospital stay (6.77 ± 1.57 vs. 4.98 ± 1.89 days). Compilations occurred in three patients in CMR group and two in PMR. Recurrence was confirmed by cystoscopy in three patients during 3–103-month follow-up, CMR group with 1 and PMR with 2.

Conclusion

In our study, we found PMR was equally effective and safe as CMR. Moreover, it is more minimally invasive, painless and economical. Therefore, we believe it is unnecessary to completely mobilize the kidney in RRPLD for intractable chyluria.

Cheng JT, Mohan S, Nasr SH et al (2006) Chyluria presenting as milky urine and nephrotic-range proteinuria. Kidney Int 70:1518–1522CrossRefPubMed

Diamond E, Schapira HE (1985) Chyluria- a review of the literature. Urology 26:427–431CrossRefPubMed

Graziani G, Cucchiari D, Verdesca S et al (2010) Chyluria associated with nephrotic-range proteinuria: pathophysiology, clinical picture and therapeutic options. Nephron. Clin pract 119:c248–253CrossRef

Tandon V, Singh H, Dwivedi US et al (2004) Filarial chyluria: Long-term experience of a university hospital in India. Int J Urol 11:193–198CrossRefPubMed

Punekar SV, Kelkar AR, Prem AR et al (1997) Surgical disconnection of lymphorenal communication for chyluria: a 15-year experience. Br J Urol 80:858–863CrossRefPubMed

Hemal AK, Gupta NP (2002) Retroperitoneoscopic lymphatic management of intractable chyluria. J Urol 167:2473–2476CrossRefPubMed

Zhang X, Ye ZQ, Chen Z et al (2003) Comparison of open surgery versus retroperitoneoscopic approach to chyluria. J Urol 169:991–993CrossRefPubMed

Zhang XU, Zhu QG, Ma X et al (2005) Renal pedicle lymphatic disconnection for chyluria via retroperitoneoscopy and open surgery: report of 53 cases with followup. J Urol 174:1828–1831CrossRefPubMed

Schneider J, Zaid UB, Breyer BN et al (2010) Chyluria associated with radiofrequency ablation of renal cell carcinoma. J Comput Assist Tomogr 34:210–212CrossRefPubMedPubMedCentral

10.

Kaur H, Matin SF, Javadi S et al (2011) Chyluria after radiofrequency ablation of renal tumors. J Vasc Interv Radiol 22:924–927CrossRefPubMed

11.

Goel S, Mandhani A, Srivastava A et al (2004) Is povidone iodine an alternative to silver nitrate for renal pelvic instillation sclerotherapy in chyluria? BJU Int 94:1082–1085CrossRefPubMed

12.

Shrestha A, Shrestha PM, Verma R (2014) Is single dose povidone iodine sclerotherapy effective in chyluria? Int Urol Nephrol 46:1059–1062CrossRefPubMed

13.

Terashi H, Tahara S, Shibuya H et al (2003) Treatment of filarial chyluria with lymphovenous shunt anastomosis: report of three cases in Japan. Plast Reconstr Surg 112:1049–1053CrossRefPubMed

14.

Zhang CJ, Chen RF, Sun XQ et al (2011) Comparison of two approaches to retroperitoneoscopic renal pedicle lymphatic disconnection for chyluria. J Endourol 25:1161–1165CrossRefPubMed

15.

Zhang Y, Ye J, Wu G et al (2011) Transumbilical laparoendoscopic single-site renal pedicle lymphatic disconnection for refractory chyluria. J Endourol 25:1337–1341CrossRefPubMed

16.

Liu B, Zhang J, Li J et al (2014) Modified retroperitoneoscopic renal pedicle lymphatic disconnection for intractable chyluria. Urology 83:1195–1198CrossRefPubMed

17.

Karmali RJ, Suami H, Wood CG et al (2014) Lymphatic drainage in renal cell carcinoma: back to the basics. BJU Int 114:806–817CrossRefPubMed

18.

Zhang CJ, Chen RF, Zhu HT et al (2012) Retroperitoneoscopic renal pedicle lymphatic disconnection for chyluria in presence of complex renal vasculature. Urology 80:1273–1276CrossRefPubMed

Title: It is unnecessary to completely mobilize the kidney in retroperitoneoscopic renal pedicle lymphatic disconnection for intractable chyluria
Authors: Tao Zhang
Jinyou Wang
Dexin Yu
Jiaxing Ma
Haoqiang Shi
Liangkuan Bi
Dongdong Xie
Yi Wang
Jie Min
Publication date: 01-10-2016
Publisher: Springer Netherlands
Published in: International Urology and Nephrology / Issue 10/2016
Print ISSN: 0301-1623
Electronic ISSN: 1573-2584
DOI: https://doi.org/10.1007/s11255-016-1351-7

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Materials and methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 10/2016

Prostate health index (PHI) and prostate-specific antigen (PSA) predictive models for prostate cancer in the Chinese population and the role of digital rectal examination-estimated prostate volume

Commentary on: Comparison of complication rates related to male urethral slings and artificial urinary sphincters for urinary incontinence: national multi-institutional analysis of ACS-NSQIP database

Effects of modified penoplasty for concealed penis in children

Does N-terminal pro-brain natriuretic peptide add prognostic value to the Mehran risk score for contrast-induced nephropathy and long-term outcomes after primary percutaneous coronary intervention?

Thermo-sensitive hydrogel for preventing bowel injury in percutaneous renal radiofrequency ablation

The nomogram conundrum: a demonstration of why a prostate cancer risk model in Turkish men underestimates prostate cancer risk in the USA

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials